ERAP1,2 in Recalcitrant Warts

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Warts DNA Virus Infections Infections Papillomavirus Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Viral Skin and Connective Tissue Diseases Tumor Virus Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

faculty of medicine Benha University

Banhā, Qalyubia Governorate, 13511, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.

Exclusion criteria

Patients with genital warts
Patients on systemic steroids or other immunosuppressive treatments
Immunocompromised individuals
Patients suffering from chronic systemic diseases
Pregnant women

Treatment and study plan

endoplasmic reticulum Aminopeptidase 1 and 2

Diagnostic Test

endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

Diagnostic Test

endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

Other names: SEUM ERAP1 MEASUREMENT USING ELISA, SERUM ERAP2MEASUREMENT USING ELISA

Primary outcomes

SERUM LEVELS OF endoplasmic reticulum aminopeptidase 1 and 2

Time frame: ONE YEAR

using specific Commercial human ELISA kits

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Serum ERAP1 and ERAP2 Levels in Patients With Recalcitrant Warts

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2024
First posted: Feb 18, 2025
Registry last updated: Feb 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed